Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01666977 · ClinicalTrials.gov registry record · Phase 1
Phase 1b/2 Trial of AMG386 With Pemetrexed and Carboplatin in Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT01666977 is a Phase 1 study that has completed, run by Amgen. The registered enrollment target is 36 participants.
The verdict
NCT01666977, a Phase 1 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
The purpose of this phase 1b/2 study is to estimate the treatment effect of study drug measuring progression free survival.
Interventions
- DRUG Carboplatin
- DRUG Pemetrexed
- DRUG AMG 386
- DRUG AMG 386 Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2012-08 |
| Est. Completion | 2015-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01666977
The ClinicalTrials.gov registry entry for NCT01666977 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Carboplatin is the first listed.
NCT01666977 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01666977 about?
NCT01666977 is a clinical study titled "Phase 1b/2 Trial of AMG386 With Pemetrexed and Carboplatin in Non-Small Cell Lung Cancer". The purpose of this phase 1b/2 study is to estimate the treatment effect of study drug measuring progression free survival.
What is the current status of trial NCT01666977?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2012-08. Estimated completion is 2015-11.
What interventions are being tested in trial NCT01666977?
The interventions under investigation include: Carboplatin (DRUG), Pemetrexed (DRUG), AMG 386 (DRUG), AMG 386 Placebo (DRUG).
Who is sponsoring clinical trial NCT01666977?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.